专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1987003600A1 CELL-FREE T CELL ANTIGEN RECEPTOR AND ITS CLINICAL UTILITIES 审中-公开
标题翻译：细胞免疫细胞抗原受体及其临床应用
公开(公告)号：WO1987003600A1
公开(公告)日：1987-06-18
申请号：PCT/US1986002591
申请日：1986-12-02
申请人： T CELL SCIENCES, INC.
发明人： T CELL SCIENCES, INC. , KUNG, Patrick, C. , IP, Stephen, H. , BROWN, Michael, C.
IPC分类号： C07K03/00
CPC分类号： C07K16/2809 , A61K38/00 , A61K39/00 , C07K14/7051 , G01N33/56972 , G01N2333/7051 , Y10S530/83
摘要： Cell-free or released T cell antigen receptors, immunoassays which allowed detection of the released T cell antigen receptor in cell culture supernatants, cell lysates, and biological fluids, as well as diagnostic and therapeutic compositions and methods for monitoring and treating certain diseases or disorders which elicit or involve a T cell response. The released T cell antigen receptors described herein differ from the cell membrane bound antigen receptors and appear to exist in a variety of forms, some of which may be complexed with other T cell determinants such as the T3 antigen. Despite the size heterogeneity of the released T cell antigen receptors or receptor/complexes, these may be reliably identified using anti-receptor antibodies, including, but not limited to, anti-major framework, anti-minor framework and anti-clonotypic antibodies which define particular epitopes of the released T cell receptor or receptor/complex.
摘要翻译：无细胞或释放的T细胞抗原受体，允许检测细胞培养上清液，细胞裂解物和生物流体中释放的T细胞抗原受体的免疫测定，以及用于监测和治疗某些疾病或病症的诊断和治疗组合物和方法其引发或涉及T细胞应答。本文所述释放的T细胞抗原受体不同于细胞膜结合的抗原受体，并且似乎以多种形式存在，其中一些可与其它T细胞决定簇如T3抗原复合。尽管释放的T细胞抗原受体或受体/复合物的大小异质性，但是可以使用抗受体抗体可靠地鉴定这些抗体，包括但不限于抗主要框架，抗小结构和抗克隆型抗体，其定义释放的T细胞受体或受体/复合物的特异性表位。

2. 发明申请

WO1987005912A1 THERAPEUTIC AND DIAGNOSTIC METHODS USING SOLUBLE T CELL SURFACE MOLECULES 审中-公开
标题翻译：使用可溶性T细胞表面分子的治疗和诊断方法
公开(公告)号：WO1987005912A1
公开(公告)日：1987-10-08
申请号：PCT/US1987000430
申请日：1987-03-03
申请人： T CELL SCIENCES, INC.
发明人： T CELL SCIENCES, INC. , KUNG, Patrick, C. , IP, Stephen , BROWN, Michael , MacKEEN, Linda, A.
IPC分类号： C07K15/00
CPC分类号： G01N33/566 , C07K16/2812 , C07K16/2815 , G01N33/564 , G01N33/56972 , G01N33/56983 , G01N33/56988 , G01N33/571 , G01N33/57407 , G01N33/57423 , G01N33/57488 , G01N33/6869 , G01N2333/715 , G01N2800/102 , G01N2800/245 , Y10S435/81 , Y10S435/975 , Y10S436/811 , Y10S436/813 , Y10S530/806
摘要： Measurement of soluble T cell growth factor receptors, soluble T cell differentiation antigens, or related soluble molecules or fragments thereof, and the use of such measurements in the diagnosis and therapy of diseases and disorders. The measurement of such molecules can be valuable in monitoring the effect of a therapeutic treatment on a subject, detecting and/or staging a disease in a subject, and in differential diagnosis of a physiological condition in a subject. These measurements can also aid in predicting therapeutic outcome and in evaluating and monitoring the immune status of patients. In specific embodiments, measurements of serum or plasma interleukin-2 receptor levels can be made, to detect or stage leukemia or lymphoma. In other embodiments, IL2R levels, or CD8 levels, can be used to differentially diagnose renal allograft rejection, as distinguished from Cyclosporing A nephrotoxicity. In another embodiment, CD8 levels can be measured to differentially diagnose rheumatoid arthritis, as distinct from other joint diseases. In particular embodiments, measurements of the soluble T cell surface molecules can be accomplished by sandwich enzyme immunuoassays.
摘要翻译：可溶性T细胞生长因子受体，可溶性T细胞分化抗原或其相关的可溶性分子或其片段的测量，以及这些测量在诊断和治疗疾病和病症中的应用。这些分子的测量在监测受试者的治疗效果，检测和/或分期受试者的疾病以及受试者的生理状态的鉴别诊断中是有价值的。这些测量还可以帮助预测治疗结果，并评估和监测患者的免疫状态。在具体实施方案中，可以进行血清或血浆白细胞介素-2受体水平的测量，以检测或分期白血病或淋巴瘤。在其它实施方案中，IL2R水平或CD8水平可用于差异诊断肾同种异体移植排斥，区别于环孢菌素A肾毒性。在另一个实施方案中，可以测量CD8水平以差异性地诊断与其它关节疾病不同的类风湿性关节炎。在具体实施方案中，可溶性T细胞表面分子的测量可以通过夹心酶免疫测定来完成。

3. 发明申请

WO1990006758A1 MONOCLONAL ANTIBODIES REACTIVE WITH DEFINED REGIONS OF THE T CELL ANTIGEN RECEPTOR 审中-公开
标题翻译：与细胞抗原受体的定义区域反应的单克隆抗体
公开(公告)号：WO1990006758A1
公开(公告)日：1990-06-28
申请号：PCT/US1989005601
申请日：1989-12-14
申请人： T CELL SCIENCES, INC.
发明人： T CELL SCIENCES, INC. , SKIBBENS, Robert, V. , HENRY, Larry, D. , RITTERSHAUS, Charles, W. , TIAN, Wei-Tao , IP, Stephen, H. , KUNG, Patrick, C. , SNIDER, Mary, Ellen , KO, Jone-Long , WOOD, Nancy, L.
IPC分类号： A61K35/14
CPC分类号： C07K16/2809 , A61K38/00 , A61K2039/505 , C07K2317/74 , Y10S436/804 , Y10S436/811
摘要： The present invention relates to monoclonal antibodies which recognize defined regions of the T-cell receptor (TCR). In a specific embodiment, the invention provides monoclonal antibodies which are reactive with a constant region of the alpha chain of the TCR. In particular embodiments, the invention relates to two monoclonal antibodies, termed αF1 and αF2, which react with two different epitopes on the framework region of the α monomer of the TCR molecule. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the beta chain of the TCR. In particular, the invention provides two monoclonal antibodies, termed W112 and 2D1, which react with β chain variable regions Vβ5.3 and Vβ8.1, respectively. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the delta chain of the TCR. In particular, the invention provides monoclonal antibody δTCS1, isotype IgG2a. The monoclonal antibodies of the invention have value in diagnosis and therapy and are useful tools for study of the immune system.

4. 发明申请

WO1990004180A1 THERAPEUTIC AND DIAGNOSTIC METHODS USING SOLUBLE T CELL SURFACE MOLECULES 审中-公开
标题翻译：使用可溶性T细胞表面分子的治疗和诊断方法
公开(公告)号：WO1990004180A1
公开(公告)日：1990-04-19
申请号：PCT/US1989004413
申请日：1989-10-05
申请人： T CELL SCIENCES, INC.
发明人： T CELL SCIENCES, INC. , KUNG, Patrick, C. , IP, Stephen, H. , BROWN, Michael, C. , MACKEEN, Linda, A.
IPC分类号： G01N33/535
CPC分类号： C07K16/2812 , C07K16/2815 , G01N33/564 , G01N33/56977 , G01N33/56988 , G01N33/57488 , G01N33/6869 , G01N2333/71 , G01N2800/102 , G01N2800/245
摘要： The present invention is directed to the measurement of soluble T cell growth factor receptors, soluble T cell differentiation antigens, or related soluble molecules or fragments thereof, and the use of such measurements in the diagnosis and therapy of diseases and disorders. Specific embodiments involve the diagnosis and monitoring of therapy using absolute values of such soluble molecules. Further embodiments involve detecting a change in the levels of such soluble molecules, in the diagnosis and therapy of diseases and disorders. In specific embodiments, detection of increases in both soluble IL2R and creatinine in the body fluid of a transplant patient can be used to differentially diagnose renal allograft rejection from infection. The invention is also directed to methods for measurement of soluble CD4 antigens, which measurements can be used, in a specific embodiment, to diagnose a state of immune activation, to diagnose rheumatoid arthritis, or to stage adult T cell leukemia in a patient. In another embodiment, soluble CD4 levels can be used to monitor the efficacy of disease treatments, a specific embodiment including monitoring therapy of HIV-infected patients. In another aspect, the invention relates to the detection, staging, or monitoring of therapy of diseases and disorders by measuring a plurality of soluble T cell markers.
摘要翻译：本发明涉及可溶性T细胞生长因子受体，可溶性T细胞分化抗原或相关的可溶性分子或其片段的测量，以及这些测量在疾病和病症的诊断和治疗中的应用。具体实施方案涉及使用这种可溶性分子的绝对值来诊断和监测治疗。进一步的实施方案涉及在疾病和病症的诊断和治疗中检测这些可溶性分子的水平的变化。在具体实施方案中，移植患者的体液中可溶性IL2R和肌酐两者的增加的检测可用于差异诊断感染的肾同种异体移植物排斥反应。本发明还涉及用于测量可溶性CD4抗原的方法，在具体实施方案中可以使用该测量来诊断患者的免疫激活状态，诊断类风湿性关节炎或阶段性成年T细胞白血病。在另一个实施方案中，可溶性CD4水平可用于监测疾病治疗的功效，一个具体实施方案包括监测HIV感染患者的治疗。另一方面，本发明涉及通过测量多种可溶性T细胞标记来检测，分期或监测疾病和病症的治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式